Daily Digest — September 26, 2026

Just Filed

Regenlab USA (RGNA) — Swiss Biologics, Nasdaq Ambitions

RGNA · Initial S-1 · terms not yet set · Nasdaq

Regenlab USA makes platelet-rich plasma (PRP) kits and biologics used in wound care and orthopedic applications — a Swiss-origin device company with CE markings dating to 2003 and FDA clearances across its core product lines. Two products — RegenKit PRP and Cellular Matrix — account for roughly 90% of revenue, which ran at $49.2 million for the most recent full year, with H1 2026 revenues of $29.3 million representing 21% growth over the prior-year period. A distribution agreement with MiMedx — valued at $10 million with $5 million received upfront — appears to be the primary driver of that acceleration.

The clinical foundation is real: 70 granted patents, 300 supporting clinical studies, and 120 distributor agreements across global markets. The financial foundation is less sturdy. The company carries a working capital deficit of $12.8 million, with current liabilities of $35.1 million against cash on hand of $4.8 million. Net income for the most recent full year was negative $1.24 million. The filing discloses proceeds earmarked heavily toward sales and marketing — $18 million of the planned raise, or 60% — with $9 million targeted at R&D and regulatory work.

Pre-IPO, insiders hold voting control at 98.64%. Terms not yet set.

---

TCGX Acquisition Corp. II — The Second Healthcare SPAC

No ticker assigned · Initial S-1 · up to $100 million · Nasdaq

TCGX Acquisition Corp. II is a blank-check company hunting for a healthcare or life sciences acquisition. The sponsor is TCG Crossover Management, a Palo Alto-based crossover fund reporting $5.1 billion in regulatory AUM. The structure is standard: 10 million Class A ordinary shares at $10.00 per share, all IPO proceeds held in trust, a 720-day combination deadline, and a forward purchase commitment of at least $20 million available to backstop a deal.

The structural detail worth noting: the same sponsor launched TCGX Acquisition Corp. — a nearly identical $86.25 million healthcare SPAC — with the same officers and directors running both vehicles simultaneously. Two blank checks, one deal team, same sector. The sponsor paid $25,000 for the 2.5 million founder shares that represent 20% of post-IPO shares outstanding — the standard promote. Post-IPO, the sponsor holds 22.1% of ordinary shares outstanding.

Whether TCGX can source and close a quality deal — and whether running two simultaneous SPACs dilutes that capacity — is the entire thesis. Terms not yet final.